As a triple incretin receptor agonist, it: Activates GLP-1 receptors , reducing appetite, slowing gastric emptying, and improving insulin secretion Activates GIP receptors , enhancing insulin response and potentially supporting fat metabolism Activates glucagon receptors , increasing energy expenditure and hepatic glucose output Whilst glucagon receptor activation increases hepatic glucose output, the net glycaemic effect of retatrutide is mitigated by the concurrent GLP-1 and GIP activity, resulting in overall improvements in glycaemic control in trial participants
When the body shifts from burning glucose to metabolising fat for fuel, it produces ketone bodies including acetone which are exhaled and can create a distinctive fruity or nail-varnish-like odour
Here's what the difference looks like in practice
If youre looking for a smarter, safer path to fat loss, the GLP-1 revolution may be the solution youve been waiting for
Medical research: if depression were cancer
KLOW components provide critical support